DRL_Tocilizumab is a proposed biosimilar medication being tested for its effectiveness, safety, and ability to trigger an immune response in patients. It is used in the treatment of moderate to severe rheumatoid arthritis. This medication is administered by injection under the skin and is being compared to an existing treatment to see if it works just as well.

RoActemra is a reference medication already used to treat moderate to severe rheumatoid arthritis. It is also given by injection under the skin. This medication helps reduce inflammation and pain in the joints by targeting specific proteins in the body that cause these symptoms.

Methotrexate is a medication commonly used in combination with other treatments for rheumatoid arthritis. It helps to reduce inflammation and slow down the progression of the disease. Methotrexate is taken regularly to help manage symptoms and improve joint function.

Rheumatoid Arthritis – Rheumatoid arthritis is a chronic inflammatory disorder that primarily affects the joints. It typically causes pain, swelling, and stiffness in the joints, often starting in the hands and feet. Over time, it can lead to joint damage and deformities. The disease progresses through periods of flares and remissions, where symptoms can worsen or improve. It can also affect other parts of the body, including the skin, eyes, lungs, and blood vessels. The exact cause is unknown, but it involves the immune system attacking the body’s own tissues.